Seeking Alpha

MissionIR's  Instablog

MissionIR
Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
MissionIR
My blog:
MissionIR Blog
  • Galena Biopharma, Inc. (GALE) Pipeline Products Include Immunotherapy Cancer Treatments 1 comment
    Feb 3, 2014 2:17 PM | about stocks: GALE

    Galena Biopharma is focused on discovering, developing, and commercializing innovative therapies addressing major unmet medical needs using targeted biotherapeutics.

    Abstral, the Company's sublingual formulation of fentanyl citrate, provides statistically significant and rapid relief of breakthrough cancer pain for patients with all types of cancer, providing improvements in pain-related daily function and patient quality of life. Currently in clinical trials, though, is NeuVax (neliepimut-S or E75), one of Galena's cancer immunotherapy treatments.

    The immunotherapy of cancer aims at specifically activating cells of the immune system, especially the so-called cytotoxic T-cells ("killer T-cells") to seek out and eliminate tumor cells while not harming healthy tissue.

    NeuVax works by turning on the immune system. It recruits the main components of the cellular immune system to fight cancer by presentation of a T-cell peptide epitope in the context of the peptide-HLA-T-cell receptor complex-effectively using the patient's own immune system (i.e., nature's own defense system against foreign or harmful germs) for the treatment of the cancer.

    Folate Binding Protein-E39 (NYSE:FBP), another Galena treatment, is a targeted vaccine aimed at preventing the recurrence of ovarian, endometrial, and breast cancers. It has very limited tissue distribution and expression in non-malignant tissue making it an ideal immunotherapy target.

    The FBP vaccine consists of the E39 peptide derived from the folate binding protein combined with the immune adjuvant granulocyte macrophage colony stimulating factor (GM-CSF), and is specifically used to treat endometrial and ovarian cancers.

    Ideally, a vaccine is specific and should only affect the cancer cells and not attack normal cells. Cancer immunotherapy causes the immune system to make antibodies to one or several specific antigens, and/or make killer T cells to attack cancer cells that express those antigens. Similar to prophylactic vaccines, Galena's cancer immunotherapies can be delivered with adjuvants, which are designed to boost the immune response.

    For more information, visit the website at galenabiopharma.com

    MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com

    Stocks: GALE
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (1)
Track new comments
  • pwd9398
    , contributor
    Comments (54) | Send Message
     
    I am long $GALE and I can only hope that a better retort to this weekend's bearish articles is forthcoming. A handful of SA commenters and contributors managed to provide well-researched rebuttals to the "Red Flag" article in a matter of hours, and this is what GALE's SA reply is two days later?

     

    We longs (and those on the fence deciding whether to become longs) don't need a four-paragraph summary of GALE'S pipeline. We know the pipeline. We need rational, fact-based responses to some serious allegations that have been made of the co., its drugs and its management.

     

    Someone recently quoted Dr. Ahn as saying it was his "fiduciary duty" to pursue a previous lawsuit... I think it goes without saying that it is his fiduciary duty to respond to troubling accusations on one of the biggest internet platforms for the discussion of biotech companies. RS and the others can't (and shouldn't have to) beat the company drums by themselves.

     

    Long GALE, but not averse to taking my profits now if management does not issue a proper statement soon.
    3 Feb, 05:54 PM Reply Like
Full index of posts »
Latest Followers

StockTalks

More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.